|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
5R44CA124032-03
|
$1,902,504
|
$1,902,504
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-39S1
|
$249,624
|
$9,985
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S2
|
$249,624
|
$9,985
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
3P30CA013330-39S3
|
$74,922
|
$2,997
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
5P30CA013330-39
|
$3,725,702
|
$149,028
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Targeting Cancer Cells with Functionalized Nanoparticle Libraries
|
1R21CA157366-01
|
$175,000
|
$175,000
|
LEVY, MATTHEW
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Genomics and Predictive Modeling of Prostate Cancer Heath Disparity
|
1U01CA158431-01
|
$357,686
|
$357,686
|
OSTRER, HARRY
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
5U10CA014958-37
|
$99,689
|
$1,994
|
Sparano, Joseph
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Skp2 in androgen-dependent proliferation of prostate cancer cells
|
5R01CA127901-03
|
$300,705
|
$300,705
|
ZHU, LIANG
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.
|
5U01CA098710-08
|
$288,303
|
$144,152
|
GAPSTUR, SUSAN
|
AMERICAN CANCER SOCIETY, INC.
|
|
Community Clinical Oncology Program
|
5U10CA037422-24
|
$4,282,002
|
$1,370,241
|
BRUNER, DEBORAH
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
RTOG Biospecimen Repository
|
2U24CA114734-06
|
$1,040,063
|
$104,006
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Radiation Therapy Oncology Group
|
3U10CA021661-35S1
|
$2,923,989
|
$1,257,315
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
RTOG Tissue Bank
|
3U24CA114734-05S2
|
|
$0
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-35
|
$10,630,221
|
$4,570,995
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
TAS::75 0849::TAS TOPIC 255: A NOVEL, NON-COMPETITIVE ANDROGEN RECEPTOR INHIBITOR
|
N43CO110095-000
|
$200,000
|
$200,000
|
BLACKBURN, DR. BRENT
|
ARTA BIOSCIENCE, INC.
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-22
|
$406,165
|
$56,863
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Comprehensive Tumor Microenvironment Based Prediction Models in Prostate Cancer
|
1R01CA140734-01A1
|
$324,738
|
$324,738
|
Ayala, Gustavo
|
BAYLOR COLLEGE OF MEDICINE
|
|
Role of FGFR1 signaling in distinct cell lineages in prostate cancer progresssion
|
5U01CA141497-03
|
$698,955
|
$698,955
|
ITTMANN, MICHAEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
Bioflavonoid Effects on EGF Signaling and Cell Cycle Pathways in Prostate Cancer
|
5R01CA128932-03
|
$308,958
|
$308,958
|
MARKAVERICH, BARRY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-05S1
|
$75,000
|
$9,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-05
|
$2,934,758
|
$352,171
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
DNA Repair and Replication Re-start in vivo
|
5R01CA085777-08
|
$291,579
|
$29,158
|
Rosenberg, Susan
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mesenchymal Derived Growth Factors in Prostatic Cancer
|
5R01CA058093-18
|
$261,747
|
$261,747
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Integrative Metabolomics of Prostate Cancer Progression
|
7R01CA133458-04
|
$328,433
|
$328,433
|
Sreekumar, Arun
|
BAYLOR COLLEGE OF MEDICINE
|
|
Characterization of prostatic stem cells and prostate cancer-initiating cells
|
3R00CA125937-05S1
|
$56,457
|
$56,457
|
Xin, Li
|
BAYLOR COLLEGE OF MEDICINE
|
|
Characterization of prostatic stem cells and prostate cancer-initiating cells
|
5R00CA125937-05
|
$234,496
|
$234,496
|
Xin, Li
|
BAYLOR COLLEGE OF MEDICINE
|
|
MECHANISMS OF SRC ACTIVATION AND ITS ROLE IN LATENT BONE METASTASIS OF BREAST AND
|
4R00CA151293-02
|
$241,529
|
$60,382
|
ZHANG, XIANG
|
BAYLOR COLLEGE OF MEDICINE
|
|
Virginia Mason Community Clinical Oncology Program
|
2U10CA035192-27A1
|
$569,700
|
$79,758
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Feasibility of a New Thermo-brachytherapy Seed for Concurrent Brachytherapy and H
|
1R41CA153681-01A1
|
$115,968
|
$115,968
|
PARSAI, E
|
BEST MEDICAL INTERNATIONAL, INC.
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-13
|
$95,412
|
$1,908
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting AR-NCoR Interaction in Prostate Cancer
|
5R01CA111803-05
|
$313,310
|
$313,310
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The Role of PTEN and the PI3K Pathway in Prostate Cancer
|
5P01CA089021-10
|
$2,037,021
|
$2,037,021
|
CANTLEY, LEWIS
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Androgen Receptor Regulation by Phosphorylation
|
4R00CA135592-03
|
$241,529
|
$241,529
|
CHEN, SHAOYONG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A Platform for Cancer Biomarker Validation: Image Fusion Using NIR Fluorescence
|
5R01CA134493-03
|
$706,671
|
$706,671
|
FRANGIONI, JOHN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Stromal Regulation of Bone Metastasis
|
1U54CA163191-01
|
$925,878
|
$925,878
|
KALLURI, RAGHU
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
PTEN and ontogenesis and tumor suppression
|
5R01CA082328-14
|
$340,612
|
$85,153
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Role of POZ-zinc finger proteins in tumorigenesis.
|
5R01CA102142-07
|
$330,937
|
$109,209
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A metabolic role for PML in tumor suppression
|
5R01CA142780-02
|
$350,219
|
$87,555
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting Tumor Suppressor Phosphatases For Cancer Therapy
|
5U01CA141496-03
|
$959,368
|
$959,368
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center
|
5U01CA113913-07
|
$699,142
|
$699,142
|
SANDA, MARTIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting prostate cancer stem cells to delay prostate cancer progression
|
1R21CA153355-01A1
|
$189,225
|
$189,225
|
ZHOU, JIN-RONG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-02S1
|
$140,000
|
$28,000
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-02S2
|
$299,726
|
$59,945
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
5U10CA139519-02
|
$685,482
|
$137,096
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
Combination Therapies for Cancer Treatment
|
5R01CA049248-21
|
$328,240
|
$164,120
|
WAXMAN, DAVID
|
BOSTON UNIVERSITY
|
|
Quantitative Analysis of Tumor Cell Migration in Three Dimensioinal Matrices
|
5R01CA132633-05
|
$279,334
|
$279,334
|
Zaman, Muhammad
|
BOSTON UNIVERSITY
|
|
Mechanisms of Action and Signaling by Steroid Hormone Antagonists
|
5R01CA101992-07
|
$252,463
|
$252,463
|
Faller, Douglas
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Heat shock proteins in signaling and cancer
|
5R01CA081244-13
|
$344,929
|
$103,479
|
SHERMAN, MICHAEL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Cancer and Leukemia Group B
|
3U10CA031946-30S1
|
$3,449,605
|
$448,449
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
Total relevant funding to Prostate for this search: $288,326,756
|